Cost utility of drugs for multiple sclerosis. Methods used don't calculate true benefit
Richards, R.; Burls, A.; Payne, N.
Bmj 320(7247): 1475; Author Reply 1475-6
2000
ISSN/ISBN: 0959-8138 PMID: 10877570 Document Number: 513286
Document emailed within 1 workday
Related Documents
Rubio-Terrés, C.; Domínguez-Gil Hurlé, A. 2005: Cost-utility analysis of relapsing-remitting multiple sclerosis treatment with azathioprine or interferon beta in Spain Revista de Neurologia 40(12): 705-710MacDonald, R. 2000: Cost effectiveness of multiple sclerosis drugs remains unknown Bmj 321(7258): 399
Duff, P.; Dolphin, C. 2007: Cost-benefit analysis of assistive technology to support independence for people with dementia – Part 2: Results from employing the ENABLE cost-benefit model in practice Technology and Disability 19(2-3): 79-90
Tissot, E.; Woronoff-Lemsi, M.C. 2001: Multiple sclerosis: cost of the illness Revue Neurologique (Paris) 157(8-9 Part 2): 1169-1174
Burnfield, A. 1997: Interferon beta in multiple sclerosis. Reducing frequency and severity of relapses will be of great clinical benefit Bmj 314(7080): 600
Grimaud, J.; Auray, J.P.; Collectif-Sep-Des-Villes-Et-Sep-Des-Champs 2004: Quality of life and economic cost of multiple sclerosis Revue Neurologique (Paris) 160(1): 23-34
Kolasa, K. 2013: How much is the cost of multiple sclerosis--systematic literature review Przeglad Epidemiologiczny 67(1): 75-9 157-60
Millar, J.A. 2019: The cost of teriflunomide in the treatment of relapsing-remitting multiple sclerosis New Zealand Medical Journal 132(1490): 36-41
Svenningsson, A.; Andersson, M.; Olsson, T. 1998: Treatment of multiple sclerosis--1. New drugs may be effective but there still are frequent relapses Lakartidningen 95(49): 5623-7 5630
Zhong, Y.; Wu, X. 2020: Effects of cost-benefit analysis under back propagation neural network on financial benefit evaluation of investment projects Plos one 15(3): E0229739
Zhang, Y.; Zhang, J.; Wang, C.; Cao, P.; Yuan, W. 2015: Cost-benefit of vertebral augmentation: how to assess the benefit Pain Physician 18(1): E97-E98
Firnhaber, W. 1972: Multiple sclerosis. Methods and results of a geomedical study Fortschritte der Medizin 90(14): 551-554
Schanke, A.K.; Grimsmo, J.; Sundet, K. 1995: Multiple sclerosis and prerequisites for driver's licence. A retrospective study of 33 patients with multiple sclerosis assessed at Sunnaas hospital Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 115(11): 1349-1352
Bykova, O.V.; Nankina, I.A.; Platonova, A.N.; Karpacheva, N.G.; Petrova, O.A.; Gorina, T.P.; Batysheva, T.T.; Serkov, S.V.; Kuzenkova, L.M. 2013: Differential diagnosis of multiple sclerosis with pediatric onset: the experience of the Moscow Division for treatment of children and adolescents with multiple sclerosis Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 113(10 Pt 2): 61-68
Laosanguanek, N.; Wiroteurairuang, T.; Siritho, S.; Prayoonwiwat, N. 2011: Reliability of the Thai version of SF-36 questionnaire for an evaluation of quality of life in multiple sclerosis patients in multiple sclerosis clinic at Siriraj Hospital Journal of the Medical Association of Thailand 94 Suppl. 1: S84-S88
Szczepanik, M.; Tutaj, M.; Filipczak-Bryniarska, I.; Bryniarski, K. 2005: Experimental methods in the treatment of multiple sclerosis--new possibilities and hopes Przeglad Lekarski 62(2): 115-118
Fryze, W.; Mirowska-Guzel, D.; Wiszniewska, M.łg.; Darda-Ledzion, L.; Członkowski, A.; Członkowska, A. 2006: Alternative methods of treatment used by multiple sclerosis patients in Poland Neurologia i Neurochirurgia Polska 40(5): 386-390
Reclos, G.J.; Baxevanis, C.N.; Sfagos, C.; Papageorgiou, C.; Tsokos, G.C.; Papamichail, M. 1987: Multiple sclerosis: II. Effects of prothymosin alpha on the autologous and allogeneic MLR in patients with multiple sclerosis Clinical and Experimental Immunology 70(2): 336-344
Gusev, E.I.; Boĭko, A.N. 2001: Some clinical and medicosocial aspects of new methods of multiple sclerosis pathogenetic treatment Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 101(12): 7-12
Kawalec, P.ł; Holko, P.ła.; Szkultecka-Debek, M.; Paszulewicz, A.; Boratyńska, M.; Głyda, M.; Ignacak, E.; Maks, J.; Russel-Szymczyk, M.; Kaweczyńska-Lasoń, A. 2013: The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 34(204): 332-338